A successful outcome to the Phase II pilot trial will also meet one of the key requirements to progress discussions with Novartis Animal Health/Elanco regarding the Option Agreement.
$2.6m cash at hand and Debt Free with no loans or liabilities.
BRI will flavour the product and increase efficacy.
Ann: Appendix 4C - Quarterly Report & Brief Company Update, page-4
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.8¢ |
Change
-0.003(1.25%) |
Mkt cap ! $87.89M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.8¢ | 19.5¢ | $29.15K | 148.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 446039 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 719518 | 6 |
View Market Depth
| Last trade - 11.11am 10/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |